Genitourinary Syndrome of Menopause; Spectroscopy, Near-Infrared; Diagnosis; Chemometrics; Atrophy, Vaginal.
The climacteric is a biological and psychosocial transition phase marked by intense hormonal changes, particularly the reduction in estrogen levels, which significantly impacts women's quality of life. Among the notable disorders that may arise, the Genitourinary Syndrome of Menopause (GSM) stands out as a frequent and underdiagnosed condition affecting between 50% and 70% of menopausal women. GSM is characterized by structural and biochemical alterations in urogenital tissues resulting from ovarian hormone deficiency and remains largely diagnosed through subjective clinical criteria. Few studies have explored the role of biomarkers in the physiopathogenesis of GSM. This study aimed to investigate the potential of Near-Infrared (NIR) spectroscopy, combined with chemometrics, for the detection of biomolecules associated with GSM in vaginal samples. An observational, analytical, case-control study was conducted, involving 81 postmenopausal women treated at a university hospital. The sample was stratified into a GSM group (n=50) and a control group (n=31). Sociodemographic and clinical data were evaluated, revealing that the GSM group presented significantly lower scores on the Vaginal Health Index (median [IQR]: 22.0 [18.0–23.0] vs. 23.0 [21.0–24.0]; p=0.01) and greater functional impairment compared to the control group. Spectral data were pre-processed and analyzed using exploratory and supervised chemometric techniques for group discrimination. Spectral analysis revealed significant differences in the regions of 970–1000, 1200–1300, 1400–1500, 1700–1800, and 1900–2000 nm, associated with hydrophilic, lipid, and protein constituents of vaginal secretions. Supervised classification models (PCA-LDA, GA-LDA, and SPA-LDA) demonstrated sensitivity, specificity, and accuracy exceeding 85% in distinguishing between cases and controls. It is concluded that NIR spectroscopy, in association with chemometrics, allows for the objective and non-invasive discrimination of molecular changes related to estrogen deficiency, showing potential as an auxiliary biomarker for GSM diagnosis and an innovation in women's healthcare.